Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk by unknown
RESEARCH ARTICLE Open Access
Lack of transforming growth factor-b signaling
promotes collective cancer cell invasion through
tumor-stromal crosstalk
Lauren A Matise1, Trenis D Palmer2, William J Ashby2, Abudi Nashabi2, Anna Chytil1, Mary Aakre1,
Michael W Pickup1, Agnieszka E Gorska1, Andries Zijlstra1,2 and Harold L Moses1,2,3*
Abstract
Introduction: Transforming growth factor beta (TGF-b) has a dual role during tumor progression, initially as a
suppressor and then as a promoter. Epithelial TGF-b signaling regulates fibroblast recruitment and activation.
Concurrently, TGF-b signaling in stromal fibroblasts suppresses tumorigenesis in adjacent epithelia, while its
ablation potentiates tumor formation. Much is known about the contribution of TGF-b signaling to tumorigenesis,
yet the role of TGF-b in epithelial-stromal migration during tumor progression is poorly understood. We
hypothesize that TGF-b is a critical regulator of tumor-stromal interactions that promote mammary tumor cell
migration and invasion.
Methods: Fluorescently labeled murine mammary carcinoma cells, isolated from either MMTV-PyVmT transforming
growth factor-beta receptor II knockout (TbRII KO) or TbRIIfl/fl control mice, were combined with mammary
fibroblasts and xenografted onto the chicken embryo chorioallantoic membrane. These combinatorial xenografts
were used as a model to study epithelial-stromal crosstalk. Intravital imaging of migration was monitored ex ovo,
and metastasis was investigated in ovo. Epithelial RNA from in ovo tumors was isolated by laser capture
microdissection and analyzed to identify gene expression changes in response to TGF-b signaling loss.
Results: Intravital microscopy of xenografts revealed that mammary fibroblasts promoted two migratory
phenotypes dependent on epithelial TGF-b signaling: single cell/strand migration or collective migration. At
epithelial-stromal boundaries, single cell/strand migration of TbRIIfl/fl carcinoma cells was characterized by
expression of a-smooth muscle actin and vimentin, while collective migration of TbRII KO carcinoma cells was
identified by E-cadherin+/p120+/b-catenin+ clusters. TbRII KO tumors also exhibited a twofold greater metastasis
than TbRIIfl/fl tumors, attributed to enhanced extravasation ability. In TbRII KO tumor epithelium compared with
TbRIIfl/fl epithelium, Igfbp4 and Tspan13 expression was upregulated while Col1a2, Bmp7, Gng11, Vcan, Tmeff1, and
Dsc2 expression was downregulated. Immunoblotting and quantitative PCR analyses on cultured cells validated
these targets and correlated Tmeff1 expression with disease progression of TGF-b-insensitive mammary cancer.
Conclusion: Fibroblast-stimulated carcinoma cells utilize TGF-b signaling to drive single cell/strand migration but
migrate collectively in the absence of TGF-b signaling. These migration patterns involve the signaling regulation of
several epithelial-to-mesenchymal transition pathways. Our findings concerning TGF-b signaling in epithelial-stromal
interactions are important in identifying migratory mechanisms that can be targeted as recourse for breast cancer
treatment.
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Introduction
Transforming growth factor beta (TGF-b) is a pleiotro-
pic cytokine that regulates growth arrest, cell motility,
development, and differentiation [1-4]. TGF-b signaling
is also instrumental in the tumor microenvironment by
influencing both tumor development and metastasis [4],
and it is frequently dysregulated in breast cancers [5-7].
In the mammary epithelium, attenuation of TGF-b sig-
naling using a dominant negative type II transforming
growth factor-beta receptor (TbRII) resulted in lobular
alveolar hyperplasia and an increased rate of tumor for-
mation in conjunction with a TGF-a transgene [8]; how-
ever, decreased pulmonary metastasis resulted when
dominant negative TbRII was expressed along with a
c-Neu transgene [8,9]. Conversely, activation or overex-
pression of TGF-b signaling in mammary carcinoma
cells expressing either the c-Neu transgene or the poly-
oma virus middle T antigen (PyVmT) transgene delayed
tumor onset but enhanced pulmonary metastasis [9-11].
Taken together, these observations suggest a tumor-sup-
pressive role of TGF-b during tumor initiation and early
tumor progression, while additionally implicating TGF-b
in promotion of late-stage tumorigenesis. Mammary-
specific ablation of TbRII also supported the role of
TGF-b as a tumor suppressor but challenged the dogma
of TGF-b as a metastatic promoter. Conditional knock-
out of TbRII in mammary epithelial cells expressing
PyVmT led to decreased tumor latency; however, in
contrast to attenuated TGF-b signaling models, TbRII
ablation increased pulmonary metastasis [12,13].
This dual role of TGF-b as both tumor suppressor and
promoter has therefore presented a dichotomy in which
TGF-b signaling is context dependent and cancer type
dependent. Consequently, epithelial-autonomous TGF-b
signaling cannot solely be responsible for influencing
tumor behavior. The tumor microenvironment, an abun-
dant source of TGF-b [4], is comprised of diverse cell
populations, such as epithelial, stromal, vascular, and
immune cells, working coordinately to promote tumor
progression. Epithelial-stromal crosstalk in tumorigenesis
has garnered much attention. It has been shown that
epithelial TGF-b signaling regulates fibroblast recruit-
ment and activation [4,14]. Concurrently, stromal TGF-b
signaling suppresses tumorigenesis in adjacent epithelia
while its ablation potentiates tumor formation [15,16].
Fibroblasts can also lead carcinoma cells along self-gen-
erated extracellular matrix tracks during carcinoma cell
migration and invasion [17]. Transient TGF-b signaling
in these invading cells can induce single motility, permit-
ting hematogeneous and lymphatic invasion [18,19]. In
contrast, lack of active TGF-b signaling results in collec-
tive invasion and lymphatic spread [18]. This illustrates
the important role of carcinoma cell TGF-b signaling in
determining the mode of cell migration and invasion.
The adaptability of invading cells is evident in multiple
forms of cell migration. Single cells invade in either an
amoeboid or mesenchymal manner characterized by
non-epithelial morphology, loss of cell-cell contacts, and
presence of actin stress fibers [20]. Whereas amoeboid
cells move through matrix pores, mesenchymal migration
additionally employs proteolytic remodeling of the extra-
cellular matrix. Collective invasion also relies on local
remodeling of the extracellular matrix [21] and occurs by
two-dimensional sheet migration or three-dimensional
group or strand migration [22]. These cellular cohorts
are heterogeneous, comprised of leading and following
cells. Leading cells, which may exemplify mesenchymal
properties, survey microenvironmental surroundings,
relay extrinsic guidance cues to following cells, and forge
clustered migration [23]. Amoeboid, mesenchymal-like,
and collective cell migration have all been identified in
breast cancer [24]. Inflammatory breast cancer, asso-
ciated with high rates of metastasis and mortality, is
marked by evidence of tumor emboli or clusters that
maintain p120 and E-cadherin expression through trans-
lational control [25]. Collective clusters are also charac-
teristic of invasive ductal carcinoma [26]. On the
contrary, lobular carcinoma frequently manifests single
cell or strand migration [3,27].
TGF-b potently stimulates cellular migration and inva-
sion of fibroblasts and epithelial cells by promoting fibro-
blast transdifferentiation into invasive myofibroblasts and
by driving an epithelial-to-mesenchymal transition (EMT)
frequently associated with invasive tumors [3,28-30].
These observations support the hypothesis that TGF-b
regulates migration patterning through tumor microenvir-
onmental interactions, such as epithelial-stromal crosstalk.
These spatially, temporally, and biologically complex inter-
actions can make in vivo TGF-b signaling studies difficult.
We therefore chose to study epithelial-stromal crosstalk
through an integrated systems analysis, combining geneti-
cally engineered mouse models and the use of the chicken
embryo chorioallantoic membrane (CAM) model [31].
Mammary tumor cells xenografted onto the CAM thrive
in large part due to robust vascularization of the nascent
tumor in the CAM. The CAM model also offers several
advantages over other model systems. First, the ex ovo
model affords long-term intravital imaging for up to 72
hours of continual imaging. Second, this model system
enables real-time tracking of cellular behavior throughout
the embryo lifespan, allowing for multiple imaging time-
points without compromising host viability. Lastly, in both
the ex ovo and in ovo models, the chicken embryo presents
minimal xenograft rejection since the embryo maintains
immature, maternal B-cell populations incapable of full
immune activity [32,33].
Using both the ex ovo and in ovo CAM models, we
characterized how tumor cell migration and invasion
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utilizes TGF-b-mediated epithelial-stromal interactions.
We found that mammary fibroblasts enhance the migra-
tory potential of carcinoma cells in either a single cell/
strand migration when epithelial TGF-b signaling is pre-
sent or in a collective migration in its absence. Further-
more, the collective migration and invasion observed
correlated with increased metastasis. Our data demon-
strate that carcinoma cell TGF-b signaling regulates
migration patterning, metastasis, and junctional protein
expression at the invasive tumor front. The data also
implicate a TGF-b-mediated cell-autonomous migratory
behavior evident only during stromal influence on
epithelial cells.
Materials and methods
Cell lines, transfection, and treatment
Mammary tumor epithelial cells - isolated from either
mouse mammary tumor virus (MMTV)-PyVmT;MMTV-
Cre;TbRIIfl/fl (transforming growth factor-beta receptor II
knockout (TbRII KO)) mice or MMTV-PyVmT;TbRIIfl/fl
(control) mice [12] - and Fsp-Cre;TbRIIfl/fl (partial TbRII
KO) fibroblasts [15] were used in xenografts for ex ovo
and in ovo CAM assays. Both types of epithelial cells were
transduced with lentiviral enhanced GFP (kind gift from
the Pietenpol Laboratory, Vanderbilt University, Nashville,
TN, USA) for intravital imaging. Fibroblasts were labeled
with a cell permeable dye (DiIC18(5)-DS; Molecular
Probes™, Eugene, OR, USA). For all cell combination
experiments, fibroblasts were used at a 2.5:1 ratio to pro-
mote the most aggressive behavior of epithelial cells (data
not shown). A human TbRII retroviral construct (plasmid
19147; Addgene, Cambridge, MA, USA) was used for
reconstitution of TGF-b signaling in TbRII KO epithelia.
Phoenix packaging cells were transfected with 8 μg con-
struct for 6 hours, followed by 48-hour viral production.
TbRII KO epithelia were then infected for 6 hours and
subsequently maintained with 1 μg/ml puromycin for
selection. Additionally, any TGF-b treatment of cell lines
was completed using 1 ng/ml TGF-b1 (R&D Systems,
Minneapolis, MN, USA) for 2.5 hours prior to RNA or
protein collection.
Ex ovo chorioallantoic membrane assay
Chicken embryos were placed into sterile weigh boats
with plastic lids at day 4 post incubation. On day 10 post
incubation, enhanced GFP-expressing breast epithelial
cells alone or in combination with fibroblasts were
grafted onto the CAM. Intravital imaging began on day
12 post incubation. Fully automated upright fluorescent
microscopes (Olympus BX61 WI and BX60 M; Olympus
America, Inc., Center Valley, PA, USA) were used for
imaging fluorescent cells. Time-lapse images were cap-
tured every 15 minutes for the duration of the experi-
ment. Analysis of cell velocity, migration distance, and
digital processing was achieved through Volocity® soft-
ware (Improvision, PerkinElmer, Inc., Waltham, MA,
USA) using protocols described previously [31]. Two-
photon microscopy of CAM tumors was subsequently
completed (Vanderbilt Cell Imaging Shared Resource,
Nashville, TN, USA). Embryonated eggs for all chicken
CAM assays were graciously provided by the Tyson Food
Corporation (Springdale, AR, USA).
In ovo chorioallantoic membrane assay
The CAM was prepared as described previously [34].
Briefly, the CAM was dropped from the eggshell on day
10 post incubation. At this time, mammary epithelial
cells alone or in combination with fibroblasts were
grafted onto the CAM. Tumor-bearing animals were
sacrificed and tumor tissue and distant CAM were col-
lected 7 to 10 days post grafting. Distant CAM was classi-
fied as any part of the CAM in which the primary tumor
was not grafted. In this way, any piece of distant CAM is
a metastatic site. To collect distant CAM at the time of
sacrifice, the eggshell was cut radially into two equivalent
halves. Two circular areas of CAM, identical in size, were
harvested from each eggshell half using a boring tool.
The resulting four pieces of CAM were then analyzed via
murine Alu PCR for the presence of disseminated cells.
Murine Alu PCR
To quantify metastatic cell dissemination in the CAM,
the CAM DNA was first extracted using the SYBR®
Green Extract-N-Amp Tissue PCR Kit (Sigma®, St.
Louis, MO, USA). DNA was then analyzed through the
use of quantitative murine Alu PCR (forward primer, 5’-
GGGCTGGTGAGATGGCTCAGTGG-3’; reverse pri-
mer, 5’-CTTCAGACACACCAGAAGAGGG-3’) [35].
Cycle threshold values were subjected to statistical
analyses after normalization to chicken glyceraldehyde-
3-phosphate dehydrogenase (forward primer, 5’-GAG-
GAAAGGTCGCCTGGTGGATCG-3’; reverse primer,
5’-GGTGAGGACAAGCAGTGAGGAACG-3’).
In ovo experimental metastasis assay
Injections were performed as previously described [34]. In
brief, fluorescently labeled carcinoma cells alone or in
combination with fibroblasts were injected intravenously
into the allantoic vein of the embryo on day 12 post incu-
bation. Initial cell arrest was assessed at 6 hours, and sub-
sequent extravasation and proliferative capability was
assessed at 18 and 24 hours (72 hours was used as an
additional timepoint). At these timepoints, cell dissemina-
tion was analyzed as described above (see In ovo chorioal-
lantoic membrane assay). To label the host chicken
vasculature, embryos were injected intravenously with
100 μl of 500 μg/ml rhodamine Lens culinaris agglutinin
(Vector Laboratories, Burlingame, CA, USA) into the
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allantoic vein. Imaging of epithelial cells and host vascula-
ture was completed using a fully automated upright
fluorescent microscope (Olympus BX61 WI). Digital
processing was achieved through Volocity® software
(Improvision).
Laser capture microdissection and expression analysis
Laser capture microdissection (LCM) was performed on
5 μm frozen in ovo tumor sections on an Arcturus Pix-
Cell IIe microscope (Molecular Devices, Sunnyvale, CA,
USA) at the Vanderbilt Translational Pathology Shared
Resource (Nashville, TN, USA). LCM-captured RNA was
isolated using an RNAqueous-Micro kit (Ambion, Aus-
tin, TX, USA) and validated for array quality (Vanderbilt
Genome Sciences Resource). Subsequent cDNA synthesis
and amplification was completed using a RT2 Nano Pre-
AMP cDNA Synthesis Kit (SA Biosciences™, Frederick,
MD, USA). Samples, three control tumors and three KO
tumors, were individually assayed on EMT RT2 Profiler™
quantitative PCR arrays (SA Biosciences™) in a Bio-Rad
iCycler (Hercules, CA, USA). Analysis was completed
using web-based RT2 Profiler™ PCR array data analysis
(SA Biosciences™). Selected gene targets were either
10-fold or greater upregulated or downregulated when
comparing our TbRII KO tumors with our TbRIIfl/fl
tumors.
Expression analysis
Total cell RNA was collected using TRIzol (Invitrogen,
Carlsbad, CA, USA) and further purified using an RNeasy
Mini Kit with RNase-Free DNase (both Qiagen, Valencia,
CA, USA). cDNA was synthesized using either Superscript
III reverse transcriptase or a SuperScript® VILO™ cDNA
Synthesis Kit (both Invitrogen) as described by the manu-
facturer. Bio-Rad iCycler and CFX96 machines were used
for quantitative PCR employing Power SYBR® Green
(Applied Biosystems, Carlsbad, CA, USA) or SsoAdvanced
SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA),
respectively. The primer sequences used to amplify murine
coding sequences of interest are presented in Table 1.
Cycle threshold values were subjected to statistical ana-
lyses after normalization to glyceraldehyde-3-phosphate
dehydrogenase.
Immunohistochemistry and immunofluorescence
In ovo tumors were harvested, fixed in 10% neutral buf-
fered formalin, paraffin embedded, and sectioned. All
immunohistochemistry and immunofluorescence
involved blocking via incubation with 3% normal goat
serum (Vector Laboratories). Immunohistochemistry for
E-cadherin and phospho-Smad2 was completed by the
Vanderbilt Translational Pathology Shared Resource. All
immunofluorescence was performed using a standard pH
6 sodium citrate buffer. Immunofluorescence data were
obtained using primary antibodies for vimentin (1:500,
PCK-594P; Covance, Emeryville, CA, USA), a-smooth
muscle actin (1:500, A2547; Sigma), E-cadherin (1:500,
610181; BD Transduction Laboratories, San Jose, CA,
USA), cytokeratin 8/18 (1:500, 20R-CP004; Fitzgerald,
Acton, MA, USA), ZO-1 (1:500, 61-7300; Zymed, San
Francisco, CA, USA), p120 (1:400, 610133; BD Transduc-
tion Laboratories), and b-catenin (1:1,000, C2206; Sigma)
by incubation overnight at 4°C. Corresponding Alexa
Fluor® secondary antibodies were used (1:1000; Invitro-
gen). Fluorescent imaging was completed on a Zeiss
Axioplan upright widefield microscope (Thornwood, NY,
USA).
Immunoblotting
Protein lysate preparation and immunoblotting proce-
dures were used as previously described [13]. Polyvinyli-
dene difluoride membranes were blocked in 5% milk in
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Tris-buffered saline-Tween® 20 and incubated with pri-
mary antibody overnight at 4°C. The following primary
antibodies were used: phospho-Smad2 (1:1,000, AB3849;
Millipore, Billerica, MA, USA), TbRII (1:4,000, sc-400;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
Wnt11 (1:1,000, ab96730; Abcam, Cambridge, MA,
USA), Tmeff1 (1:1,000, sc-98956; Santa Cruz Biotechnol-
ogy, Inc.), Versican (1:1,000, AB1033; Millipore), and
N-cadherin (1:2,500, 610920; BD Transduction Labora-
tories). Corresponding secondary horseradish peroxidase
ImmunoPure® antibodies were used (1:5,000; Pierce,
Waltham, MA, USA). Chemiluminescence detection of
protein was completed using Western Lightning® ECL
(Perkin-Elmer).
Statistical analysis
All statistical analyses were reported using two-tailed
unpaired t tests to determine significance (P < 0.05).
Results
Fibroblasts induce single cell/strand or collective
migration of epithelia
To assess the inherent migratory differences between our
murine MMTV-PyVmT TbRII KO or MMTV-PyVmT
TbRIIfl/fl control mammary carcinoma cells, an ex ovo
chicken embryo model system was employed. Initial graft-
ing was of enhanced GFP-expressing murine MMTV-
PyVmT mammary tumor epithelial cells, either TbRII KO
or TbRIIfl/fl alone, which were allowed to form discernible,
vascularized tumors for 3 days. Tumor-bearing animals
were placed in an intravital imaging chamber and tumor
cell motility was evaluated for up to 72 hours via time-
lapse imaging. We observed a consistently larger tumor
size of TbRII KO tumors compared with TbRIIfl/fl control
tumors; however, both tumors presented no evidence of
migration beyond the periphery of the primary tumor (see
Figure S1 in Additional file 1). The lack of an inherent dif-
ference in migratory activity due to the presence or
absence of TGF-b signaling in the epithelial cells con-
firmed that the previously published elevated lung metas-
tasis observed in our TbRII KO mice was not due to
enhanced cell-autonomous migratory capacity of TbRII
KO epithelial cells alone. We therefore hypothesized that
stromal influence on epithelial cells could critically alter
the migration pattern of tumor epithelial cells.
To best recapitulate tumor-stromal interactions of the
tumor microenvironment, the TbRIIfl/fl and TbRII KO
epithelial cells were combined with partial TbRII KO
mammary fibroblasts ex ovo (hereafter, fibroblasts are
grafted with epithelial cells in all tumors). Partial TbRII
KO fibroblasts were used due to their ability to invoke
more aggressive tumor behavior as compared with that of
pure TbRII KO fibroblasts or TbRII competent fibroblasts
[16]; however, each of these fibroblast cell lines were
tested in our chicken embryo model and produced similar
tumor migratory phenotypes as described below (data not
shown). For the remainder of in vivo experimentation,
only partial TbRII KO mammary fibroblasts were used.
In both TbRIIfl/fl and TbRII KO tumors, the presence of
fibroblasts caused epithelial migration away from the
tumor periphery (Figure 1A; see Figure S1 in Additional
file 1). In control TbRIIfl/fl tumors capable of TGF-b sig-
naling, the tumor cells exhibited a strand and/or single
cell migration (Figure 1A, B; see Additional file 2). Nota-
bly, collective migration was not observed in any TbRIIfl/fl
tumors. In contrast, TbRII KO tumors exhibited primarily
collective migration with occasional single cell or strand
migration (Figure 1A, B; Additional file 3). In either tumor
type, fibroblasts were always visible outside the tumor
mass beyond the periphery of invading tumor cells, reaf-
firming the concept that stromal cells lead the way for
subsequent tumor cell migration. This corroborates
in vitro data indicating that fibroblasts enhanced the inva-
sion of epithelial cells in a transwell assay (see Figure S2 in
Additional file 1). The two migratory phenotypes observed
in vivo were also affected by vascular influence in the
tumor microenvironment. Migration appeared directional,
as epithelial cells migrated along and around the vascula-
ture (Figure 1C), perhaps due to migratory cues emanating
from the vasculature or characteristics of the perivascular
matrix.
Since the fibroblasts had a pronounced effect on tumor
cell migration, a reciprocal effect of tumor cell influence
on fibroblasts was investigated. No difference in displace-
ment rate of fibroblasts from the tumor periphery was
observed regardless of their combination with either
TbRIIfl/fl or TbRII KO carcinoma cells; however, fibroblast
velocity was increased by 50% in the presence of TbRII
KO cells (Figure 1D). In this way, the TbRII KO epithelial
cells, which possess an increased propensity for lung
metastasis [12,13], responded to extrinsic stromal cues in
a heightened manner and subsequently facilitated tumor-
stromal communication. This reciprocity of tumor-stromal
interactions in driving motility and invasion is consistent
with previously observed interactions in the tumor micro-
environment of other models [4,14,15,36].
Cell migration mode can affect metastatic potential
Histological evaluation of fixed tumor tissue was used to
determine cellular morphology within the tumor. For this
purpose, mammary carcinoma cells, either TbRIIfl/fl or
TbRII KO, were combined with mammary fibroblasts
and xenografted onto the CAM in ovo. Overall tumor
histology revealed a well-differentiated, lobular morphol-
ogy in TbRIIfl/fl control tumors; however, the TbRII KO
tumors appeared less differentiated (Figure 2A). The
tumor histology is not model dependent since CAM-
xenografted tumors displayed similar morphology to that
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Figure 1 Tumor-stromal interactions promoted either single cell or collective cell invasion. Combinatorial xenografts of either enhanced
GFP-labeled transforming growth factor-beta receptor II control (TbRIIfl/fl) or transforming growth factor-beta receptor II knockout (TbRII KO)
carcinoma cells with fibroblasts (fib) were grafted onto the chorioallantoic membrane and monitored via intravital imaging. (A) Top panel, single
cell migration was exhibited in tumors that maintain epithelial transforming growth factor-beta (TGF-b) signaling. Only the epithelial channel is
shown in order to visualize the single cell and strands displayed. Bottom panel, collective migration was observed in TbRII KO tumors (arrow).
Both epithelial (green) and fibroblast (red) channels are overlayed. Fibroblasts guided both types of epithelial migration. (B) Migration types
observed when comparing TbRIIfl/fl control and TbRII KO ex ovo tumors are quantified. (C) TbRII KO tumors migrated collectively along and
around the vasculature, as shown by two-photon microscopy. Vasculature (left), epithelial (middle), and overlayed (right) panels are shown. The
fibroblasts were unlabeled and therefore not shown. (D) Fibroblasts had enhanced velocity in the presence of TbRII KO epithelial cells compared
with TbRIIfl/fl cells.
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Figure 2 Single cell and collective cell invasive aggregates demonstrated different metastatic potentials. (A) H & E sections of in ovo
tumors revealed overall tumor histology. (B) Evidence of strand filing (top left panel, arrows) and single cells (bottom left panel) were seen in H
& E sections of transforming growth factor-beta receptor II control (TbRIIfl/fl) tumors. Collective clusters were seen in transforming growth factor-
beta receptor II knockout (TbRII KO) tumors. Images are representative of the tumor periphery and tumor-stromal boundaries. (C) Results from
murine-specific Alu quantitative PCR found that collective aggregates of TbRII KO tumors achieved greater metastasis than single cells of TbRIIfl/fl
tumors in ovo. CAM, chorioallantoic membrane; fib, fibroblasts. (D) TbRII KO epithelial cells possess a greater ability than TbRIIfl/fl cells to
extravasate and survive post extravasation, quantified via an experimental metastasis assay and subsequent murine-specific Alu PCR (top graph).
All timepoints and samples were compared with the 6-hour timepoint of TbRIIfl/fl cells and fibroblasts (dashed line). Representative images of
epithelial cells (green) in relation to the lectin-labeled vasculature (red) were taken at all timepoints to confirm extravasation quantification and
are shown beneath the graph (fibroblasts were unlabeled and therefore not shown). The 6-hour timepoint represented cells that arrested in the
vasculature. Presence of carcinoma cells in the capillary bed, which is porous, was seen. At the 18-hour and 24-hour timepoints, proliferative
capability of disseminated tumor cells was seen. This was evident in cells extravasating from the capillary bed, invading into areas of the CAM in
close proximity to the vasculature, and exhibiting protrusive cellular processes. At the 72-hour timepoint, cohesive groups of cells with protrusive
cellular processes were observed near vessels.
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of the mouse models in which the grafted cells were
generated [12,13]. Immunohistochemistry for phospho-
Smad2 confirmed that TbRIIfl/fl tumors maintained
TGF-b signaling in epithelial and stromal cells, while
TbRII KO tumors lacked signaling in epithelia only (see
Figure S3 in Additional file 1). At the cellular level, it is
apparent that strand migration and numerous single
epithelial cells were visible at the tumor-stromal interface
and tumor edges of TbRIIfl/fl tumors (Figure 2B). In con-
trast, tumor cells at the tumor-stromal interface and
tumor edges of TbRII KO tumors were visible as large
clusters or cohorts. These findings corresponded with
our observations during time-lapse imaging of cell migra-
tion (Figure 1A). One potentially confounding variable in
our in ovo observations is the reproducibility with multi-
ple xenografted cell lines. Using several carcinoma and
fibroblast cell lines with the appropriate TbRII status, we
therefore confirmed an identical pattern of single cell/-
strand migration (TbRIIfl/fl tumors) or collective migra-
tion (TbRII KO tumors) (see Figure S4 in Additional
file 1).
Numerous publications have demonstrated that differ-
ential modes of cell migration can correlate with altered
metastatic ability. In order to distinguish differential
metastasis of TbRIIfl/fl or TbRII KO tumor cells, CAM
distant from the primary tumor site was harvested from
in ovo tumor-bearing animals. The amount of metastasis
was then analyzed using murine-specific Alu PCR. Metas-
tasis of collective aggregates in TbRII KO tumors was
nearly 2.5-fold higher than that of TbRIIfl/fl tumors
(Figure 2C). This data suggests that collective migration
of cells lacking TGF-b signaling appeared to present a
distinct advantage over single cell/strand migration of
cells in stromal invasion. To further substantiate our
metastatic findings, an in ovo experimental metastasis
assay using murine-specific Alu PCR was performed.
This assay detects the presence of epithelial cells in the
CAM, initially upon vascular arrest and subsequently for
extravasation and proliferative capability. TbRIIfl/fl carci-
noma cells combined with fibroblasts maintained similar
cell quantities upon vascular arrest and 18 hours post
vasculature entry; however, the presence of these
cells continued to decline over the course of the assay
(Figure 2D). This decline was attributed to the inability of
all cancer cells to survive in circulation and to the fact
that fibroblast survival in circulation has not been well
documented. In contrast to the behavior of the TbRIIfl/fl
cells and fibroblasts, although TbRII KO carcinoma cells
combined with fibroblasts resulted in a similar initial cell
decline, there was a subsequent increase for the duration
of the assay. This steady rise was attributed to better
extravasation, survival, and colonization abilities of TbRII
KO epithelia. This finding corroborates the CAM metas-
tasis results, suggesting that the collective TbRII KO
aggregates are better capable of metastasis (Figure 2C).
In both cell combinations, it was also observed that the
majority of extravasated cells were present in clusters
near vasculature, with the TbRII KO epithelia forming
more compact clusters (Figure 2D). The vascular proxi-
mity of colonizing cells supports our in ovo migratory
results demonstrating directional vasculature migration
(Figure 1C).
As confirmation of our extravasation results, an addi-
tional experimental metastasis assay was completed using
carcinoma cells alone (see in Figure S5 Additional file 1).
Although the presence of TbRIIfl/fl epithelial cells
remained constant over the course of the assay, the
TbRII KO epithelia were better able to extravasate and
survive; however, neither the TbRIIfl/fl nor the TbRII KO
epithelia had evidence of invasive cellular protrusions
that were present when epithelial cells were combined
with fibroblasts (Figure 2D; see Figure S5 in Additional
file 1). Combining these two separate experimental
metastasis assays suggests that the carcinoma cells may
innately possess an extravasation ability that is enhanced
by fibroblast presence. Investigation of intravasation cap-
ability, the initial step in metastatic dissemination,
revealed no differences between the TbRIIfl/fl and TbRII
KO epithelial cells (data not shown).
To confirm that the observed migratory phenotypes
were TbRII dependent, TbRII KO epithelial cells were
reconstituted with functional TbRII (RII) [37] to regain
responsiveness to TGF-b signaling (Figure 3A). In ovo
xenografts of TbRIIfl/fl, TbRII KO, or TbRII KO+RII
were combined with fibroblasts, and migratory pheno-
type of the tumor cells was observed. Indeed, TbRII KO
+RII epithelia showed evidence of single cell migration at
the tumor periphery, thereby recapitulating the migratory
phenotype observed in TbRIIfl/fl tumors (Figure 3B).
These results substantiated the conclusion that single cell
migration versus collective cell migration was a conse-
quence of TbRII expression.
Epithelia lacking TGF-b signaling maintain junctional
protein localization at the tumor-stromal interface
During development and tumorigenesis it is sometimes
necessary for cells to maintain polarity and junctional
adherence, albeit transiently [22,38]. This is important
for effective forward migration of epithelial sheets during
organ formation, as well as increased pressure of tumor
epithelia to push against surrounding stroma during
tumor proliferation. The divergent individual versus col-
lective migratory phenotypes of TbRIIfl/fl and TbRII KO
tumor cells observed in real-time imaging and in histolo-
gical sections suggest that molecular distinctions respon-
sible for cell-cell adhesion and migration are developed
in response to TGF-b signaling. Indeed, immunohisto-
chemical results indicated that E-cadherin expression
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was highly mislocalized in epithelia at the tumor-stromal
interface of TbRIIfl/fl tumors (Figure 4A). Higher magnifi-
cation revealed maintenance of E-cadherin membrane
localization in multicellular lobular tumor structures but
cytoplasmic localization or potential degradation in single
epithelial cells. This contrasted with E-cadherin mem-
brane localization in all collective clusters at the tumor-
stromal interface of TbRII KO tumors. To further ana-
lyze junctional characteristics of the tumor types, cyto-
keratin 8/18 was used in immunofluorescence to
distinguish epithelial cells from surrounding stromal
cells. Results indicated that p120 and b-catenin were mis-
localized in TbRIIfl/fl epithelia that possess TGF-b
signaling, corresponding to the mislocalized E-cadherin
evident in these tumors (Figure 4B, C, D). On the other
hand, E-cadherin expression in clusters of TbRII KO
tumors co-localized with both p120 and b-catenin
expression at the membrane, suggesting maintenance of
adherens junctions. Similarly, tight junctions also
remained intact in TbRII KO tumors, as assessed by
ZO-1 membrane localization, but were not maintained
in TbRIIfl/fl tumors at the tumor-stromal interface
(Figure 5A).
Since epithelial clusters in TbRII KO tumors maintained
junctional protein expression, and epithelia of TbRIIfl/fl
tumors appeared more mesenchymal, EMT-like markers
A
B
           TȕRIIfl/fl + fibroblasts                        TȕRII KO + fibroblasts                   TȕRII KO+RII + fibroblasts
50 ȝm 50 ȝm 50 ȝm




Figure 3 Single cell migration is a transforming growth factor-beta receptor II -dependent event. (A) Transforming growth factor-beta
receptor II knockout (TbRII KO) cells used for xenografting were reconstituted with a functional human TbRII construct. Transforming growth
factor-beta receptor II control (TbRIIfl/fl) cells were used as a control for active transforming growth factor beta (TGF-b) signaling as assessed by
phospho-Smad2 expression. A shorter exposure of the hTbRII blot was used for all TbRII KO lanes due to overexpression signal strength. (B)
Reconstitution of active TGF-b signaling in TbRII KO epithelia recapitulated the single cell migratory phenotype observed in TbRIIfl/fl tumors.
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were explored. As expected, epithelia in TbRIIfl/fl tumors,
marked by cytokeratin 8/18, expressed a-smooth muscle
actin and vimentin at the tumor-stromal interface and at
the edges of lobular tumor structures (Figure 5B, C, D),
confirming a mesenchymal phenotype. These observations
are consistent with the idea that single cell migration may
rely on classical mechanisms of EMT, such as loss of adhe-
rens and tight junctions and reorganization of actin stress
fibers, to drive tumor cell invasion. Interestingly, all collec-
tive clusters in TbRII KO tumors were immediately
TȕRII KO + fib
p120, cytokeratin 8/18, DAPI
TȕRIIfl/fl + fib
E-cadherin, ȕ-catenin, DAPI
TȕRII KO + fibTȕRIIfl/fl + fib













Figure 4 Epithelial cell transforming growth factor-beta signaling disrupted maintenance of E-cadherin/p120/b-catenin membrane
localization at adherens junctions. All images were taken of in ovo tumors (asterisks, tumor-stromal regions; arrows, single cells with protein
mislocalization). (A) Immunohistochemistry showed that E-cadherin was mislocalized in tumor-stromal regions in which single cells were found
in transforming growth factor-beta receptor II control (TbRIIfl/fl) tumors (top and bottom left panels). Collective clusters in the same regions
exhibited E-cadherin membrane localization in transforming growth factor-beta receptor II knockout (TbRII KO) tumors (top and bottom right
panels). (B), (C), (D) Immunofluorescence for p120, E-cadherin, and b-catenin revealed mislocalization of their expression in stromal areas of
TbRIIfl/fl tumors but maintenance in TbRII KO tumors. Cytokeratin 8/18 was used as a marker for carcinoma cell identification. DAPI, 4’,6-
diamidino-2-phenylindole; fib, fibroblasts.
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TȕRIIfl/fl + fib TȕRII KO + fib
*
D
vimentin, cytokeratin 8/18, DAPI
TȕRIIfl/fl + fib TȕRII KO + fib
*
25 um 
TȕRII KO + fibTȕRIIfl/fl + fib
                    ZO-1, cytokeratin 8/18, DAPI
*
cytokeratin 8/18, ĮSMA, DAPI
TȕRII KO + fib
TȕRIIfl/fl + fib
*
Figure 5 Epithelial cell transforming growth factor-beta signaling disrupted tight junction protein localization while enhancing
migratory expression. All immunofluorescent images were taken of in ovo tumors (asterisks, tumor-stromal regions; arrows, single cells with
protein mislocalization). Cytokeratin 8/18 was used as a marker for carcinoma cell identification. (A) ZO-1 was mislocalized in stromal areas of
transforming growth factor-beta receptor II control (TbRIIfl/fl) tumors but maintained in transforming growth factor-beta receptor II knockout
(TbRII KO) tumors. (B), (C), (D) Increased expression of a-smooth muscle actin (a-SMA) and vimentin was seen in TbRIIfl/fl tumor cells located in
tumor-stromal areas. Vimentin was expressed by fibroblasts immediately surrounding TbRII KO epithelial clusters. DAPI, 4’,6-diamidino-2-
phenylindole; fib, fibroblasts.
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surrounded by vimentin-positive adjacent fibroblasts. This
finding corroborates our ex ovo findings (Figure 1A) and
previous studies suggesting fibroblast-led migration of
epithelial cells [17].
Differing migration modes are associated with gene
expression differences in in ovo tumors
To identify gene expression changes that contribute to
motility and invasion in response to loss of TGF-b signal-
ing, we isolated tumor cells at the tumor-stromal interface
using LCM on frozen in ovo tumor sections. For TbRIIfl/fl
tumors, single migratory epithelial cells and epithelia lin-
ing the tumor-stromal interface were captured (see Figures
S6 and S7 in Additional file 1). For TbRII KO tumors,
migratory epithelial clusters in the stroma and epithelia
lining the tumor-stromal interface were captured. Samples
were then analyzed on an EMT quantitative PCR array
(Figure 6A). Epithelial purity of the LCM samples was
confirmed via PyVmT and EpCAM expression in compar-
ison with FAP expression, markers of epithelia and fibro-
blasts, respectively (Figure 6B). It is important to note that
the epithelial markers were similarly expressed in both
TbRIIfl/fl and TbRII KO LCM samples, indicating the
same quantity of epithelia in all LCM samples (Figure 6C).
Using a 10-fold or greater upregulation or downregulation
stringency for the EMT array, we identified upregulation
of Cdh2, Igfbp4, and Tspan13, as well as downregulation
of Col1a2, Bmp7, Wnt11, Gng11, Vcan, Tmeff1, and Dsc2
in TbRII KO epithelia compared with TbRIIfl/fl epithelia
(Figure 6D). These target genes shared integral roles in
cell-cell binding and growth factor signaling. Target
expression was validated via immunoblot for N-cadherin,
Vcan, and Tmeff1 (Figure 7A). Additionally, target expres-
sion of Wnt11, Tmeff1, and Dsc2 was confirmed via quan-
titative PCR on the cultured cell lines used for the in vivo
assays (Figure 7B). Interestingly, the presence of fibroblast
conditioned media induced similar gene expression
changes to those seen by the LCM epithelia that were in
the physical presence of fibroblasts. We also investigated
some genes frequently associated with collective (DDR1,
eIF4GI) [25,39] and mesenchymal migration (Snai3), but
found no significant expression difference between our
tumor types (see Figure S8 in Additional file 1).
One of the targets, Tmeff1, is a type I transmembrane
receptor with signal transduction activity and is known to
play a role in cancer progression signaling through induc-
tion of erbB4 tyrosine kinase receptor phosphorylation
[40] and suppression of Nodal signaling. Tmeff1 inhibits
Nodal signaling via binding to the Nodal co-receptor,
Cripto [41], which is overexpressed in ~70 to 80% of inva-
sive human breast cancer [42,43]. Increased expression of
Tmeff1 has previously been shown as a direct result of
Smad-dependent TGF-b signaling in the hair follicle [44].
Given that Tmeff1 is just one of several Nodal pathway
inhibitors, we explored the expression of these other inhi-
bitors. Dact2, which binds to activin type I receptors and
targets them for lysosomal degradation, was ≥ 50-fold
downregulated in TbRII KO epithelia across all in vitro
conditions tested (Figure 7C). Downregulation of SnoN,
an inhibitor of Nodal and TGF-b signaling, was also seen.
Due to the observed downregulation of Nodal inhibitors,
it might be inferred that activation of Nodal target genes
would result. Surprisingly, only the Nodal target Gsc was
upregulated in TbRII KO epithelia, while several other tar-
get genes (Mixl1, Nodal, Lefty 1/2, Ubr7, HESX1, Moap1,
Cer1) were unaffected (Figure 7C; data not shown).
Discussion
Patterns of carcinoma cell migration strikingly resemble
those in development, organogenesis, tissue remodeling,
and wound healing. During early embryogenesis EMT is
frequently observed in gastrulation, while in late embryo-
genesis EMT is characteristic of neural crest migration
[45,46]. Collective migration of epithelial sheets generates
solidified epithelial barriers in organ development. Some
of these sheets are led by tip cells that serve as a commu-
nication conduit to following cells in the cohort [23]. In
mammary branching morphogenesis, the development
and elongation of the mammary ductal tree involves col-
lective invasion of terminal end buds [22,38]. Epithelial
sheets and clusters maintain apicobasal polarity and cell-
cell junctions. In these examples of cellular processes,
cooperation is required between multiple cell popula-
tions, such as epithelial-stromal crosstalk. Evidence of
both EMT and cohesive invasion can be found in our
model of epithelial-stromal interactions within the tumor
microenvironment. Fibroblasts were required for carci-
noma cell invasion, suggesting a microenvironmental
component of cellular communication. Our cohesively
moving TbRII KO epithelia maintained adherens and
tight junctional proteins necessary for cell-cell adhesion.
The presence of vimentin-positive fibroblasts adjacent to
these clusters further supports the concept of fibroblast-
led epithelial invasion. Similar to EMT phenotypes seen
in development, our TbRIIfl/fl tumors with competent
TGF-b signaling express a-smooth muscle actin and
vimentin and lose junctional polarity.
The predominant perception of TGF-b signaling in
tumor migration has been that TGF-b induces single cell
invasion, which is correlated with increased invasive and
metastatic potential. This invasion has commonly been
associated with epithelial cells undergoing EMT, through
which they acquire mesenchymal characteristics of stro-
mal cells and presumably become invasive. Yet recent
evidence from in vitro studies finds a collective migration
component of tumors [17]. There is histological evidence
of chain or collective epithelial cell migration in human
cancer. For many years, pathologists have identified
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Figure 6 Epithelial-to-mesenchymal transition gene expression changes were seen between tumors differing in invasive phenotype.
Gene expression changes detected on an epithelial-to-mesenchymal transition (EMT) quantitative PCR array were determined upon comparison
of transforming growth factor-beta receptor II knockout (TbRII KO) isolated epithelia with transforming growth factor-beta receptor II control
(TbRIIfl/fl) isolated epithelia. (A) Identification of target genes was found by fold-change values. All highlighted genes were statistically significant
(P < 0.05) and conform to the criteria of either 10-fold or greater upregulation or downregulation when comparing the TbRII KO laser capture
microdissection (LCM) epithelia with the TbRIIfl/fl epithelia. (B) Epithelial purity of all LCM samples was confirmed when comparing PyVmT or
EpCAM epithelial marker expression with that of the FAP fibroblast marker. All expression values were compared with FAP expression in the
TbRIIfl/fl LCM sample. (C) Similar amounts of epithelia, as quantified by expression of PyVmT and EpCAM epithelial markers, were found in TbRII
KO and TbRIIfl/fl LCM samples. (D) Array target gene expression (identified in (A)) of TbRII KO LCM samples, as compared with that of TbRIIfl/fl
LCM samples, is shown with associated statistics. fib, fibroblasts.
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Figure 7 Epithelial-to-mesenchymal transition gene expression changes were confirmed using cultured cells. Cells used were the same as
those xenografted onto the chorioallantoic membrane (see Figures 1 and 2). (A) Target gene validation was confirmed by immunoblotting. For
either the transforming growth factor-beta receptor II control (TbRIIfl/fl) cells or the transforming growth factor-beta receptor II knockout (TbRII KO)
cells, the conditions were as follows: cells alone, cells treated with 1 ng/ml transforming growth factor beta (TGF-b) for 2.5 hours, cells treated with
partial TbRII KO fibroblast conditioned media for 24 hours (two cell lines used), or cells treated with TbRIIfl/fl fibroblast conditioned media for 24
hours. Conditioned media treatment from partial TbRII KO and TbRIIfl/fl fibroblasts gave similar results. (B) Wnt11, Dsc2, and Tmeff1 expression in
TbRII KO cells paralleled results seen in array results. For each condition (epithelial cells alone or fibroblast conditioned media treatment), all TbRII
KO cell samples were respectively compared with TbRIIfl/fl cells. (C) Expression of Nodal signaling inhibitors (Dact2, SnoN) was downregulated but
unaccompanied by significant expression increases of Nodal targets. For each condition (epithelial cells alone or fibroblast conditioned media
treatment), all TbRII KO cell samples were respectively compared with TbRIIfl/fl cells. CM, conditioned media; fib, fibroblasts.
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cohorts of cells in stromal areas surrounding primary
tumors [47]. In many instances, epithelial movement
occurs within the epithelial-stromal interface of the
tumor itself or at the tumor periphery. Consistent with
current views, our work suggests that the presence of
epithelial TGF-b signaling causes a single cell or strand
migration. On the other hand, a lack of epithelial TGF-b
signaling induces a collective tumor invasive front in the
tumor areas prone to increased cell movement. Fibro-
blasts were able to induce these two varying patterns of
migration. This suggests a pro-migratory effect provided
by stromal fibroblasts that enables a cell-autonomous
epithelial response dependent upon TGF-b signaling cap-
ability. A lack of TGF-b signaling has previously been
implicated in collective migration, but this was shown
through exogenous manipulation of the TGF-b pathway
[48]. Our results, using genetic, cell-autonomous control
of TGF-b signaling through expression of TbRII, specifi-
cally identified TGF-b as a critical factor involved in
epithelial migration in the tumor microenvironment. The
novelty of our findings also extended to the methodology
by which we have achieved these results. Conventional in
vivo imaging techniques afford minimal imaging length
and significant viability issues inflicted on the animals
used. The use of our cells in the CAM model enabled
prolonged imaging and minimal embryo damage at each
timepoint used for video capture.
A fluidity and plasticity between migration patterns is
crucial to cancer progression. Beyond the characteriza-
tion of tumor behavior at the primary site, the concept
of mesenchymal-to-epithelial transition at secondary
tumor sites has emerged [49-51]. In mesenchymal-to-
epithelial transition, colonized metastases are histo-
pathologically similar to the epithelial nature of the
primary tumors from which they are derived [52,53].
These metastases possess polarity markers and a re-
epithelialization that maintains junctional protein
expression. This is evident in the movement of meta-
static emboli, or clustered epithelia, which are a hall-
mark of inflammatory breast cancer [25]. Our work
supports the epithelial nature of invasive cell movement.
The collective aggregates observed in TbRII tumors
were capable of greater CAM metastasis than were cells
migrating singly or in strands that maintain TGF-b sig-
naling. Additionally, our experimental metastasis assay
results demonstrate that cells lacking TGF-b signaling
possess an enhanced ability to extravasate, survive, and
re-epithelialize at metastatic sites. The ability to colonize
at distant sites, regardless of TbRII expression and cell
quantity, is supporting evidence for an mesenchymal-to-
epithelial transition. Since no difference in intravasation
ability was found between tumors with and without
TGF-b signaling, our results suggest that the extravasa-
tion and survival steps of the metastatic cascade may be
where cells lacking TGF-b signaling have a distinct
advantage in positively contributing to metastasis.
Our results begin to pinpoint a mechanism responsi-
ble for the clustered TbRII KO epithelial invasion versus
the single cell or strand migration of TGF-b-competent
epithelia. Tmeff1 is a crucial inhibitor of the Nodal sig-
naling pathway, which is responsible for many EMT-
related effects. It is therefore noteworthy that our TbRII
KO epithelia significantly downregulated Tmeff1 yet
maintained a clustered aggregate formation during inva-
sion. We showed that other Nodal signaling pathway
inhibitors were also downregulated. Our results allude
to a significant overlap between TGF-b and Nodal sig-
naling pathways as a consequence of TbRII loss. Given
that Tmeff1 contains Smad-binding elements in its pro-
moter and has been shown to be activated in Smad-
dependent TGF-b signaling in the hair follicle [44], it is
likely also a TGF-b target in the mammary gland, a
question further being pursued. Tmeff1 may also be
regulated by a fibroblast-secreted factor in the tumor
microenvironment. Our results using fibroblast condi-
tioned media suggest that the physical presence of fibro-
blasts may not be necessary to induce gene expression
changes responsible for migration patterning. This cor-
roborates previously published studies implicating the
role of fibroblast-secreted factors in tumor cell prolifera-
tion and motility [16,54].
Our findings illustrate a critical role for TGF-b signal-
ing in the regulation of tumor microenvironmental
interactions. Epithelial-stromal signaling deserves further
study as a prominent driver of invasive and metastatic
progression. The presence of fibroblasts induces specific
carcinoma cell migration patterning dependent upon
TGF-b competency. Further characterization of single
cell migration versus collective cell migration is needed
in tumor analysis in order to better understand the con-
tribution of each to tumor progression. Upon further
investigation, it is the hope that specific patterns of
tumor invasiveness can be targeted as recourse for
breast cancer treatment.
Conclusion
Our findings implicate a role for TGF-b signaling in the
regulation of epithelial migration patterning in the tumor
microenvironment. We have shown that lack of epithelial
TGF-b signaling induces a collective invasion of epithelia
in the presence of stromal influence, while the presence
of TGF-b signaling induces a single cell or strand migra-
tion. While stromal cells are needed for induction of
epithelial invasion, we have shown cell-autonomous
migration pattern response to this stimulus. The altered
expression of Tmeff1 was also identified as a conse-
quence of these migration differences. Our results are
important in identifying invasive cellular behavior that
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can be targeted in hopes of preventing the metastatic
spread of breast cancer.
Additional material
Additional file 1: Figure S1 showing that fibroblasts caused
increased tumor growth of both TbRIIfl/fl and TbRII KO tumors (top
panels, epithelial cells alone; bottom panels, epithelia and
fibroblasts combined). Epithelial cells in green, fibroblasts overlayed in
red. Figure S2 showing that fibroblasts enhanced invasion of carcinoma
cells through Matrigel-coated (BD Biosciences) transwells after 6 hours.
Carcinoma cells were permitted to invade through Matrigel alone.
Carcinoma cells were also allowed to invade through Matrigel that had a
bottom fibroblast coating used to assess tumor-stromal interactions.
Figure S3 showing that TbRIIfl/fl tumors maintain epithelial and stromal
TGF-b signaling as indicated through phospho-Smad2 expression, while
TbRII KO tumors maintain TGF-b signaling only in the partial TbRII KO
fibroblasts. Figure S4 showing that additional TbRIIfl/fl and TbRII KO
epithelial cell lines were combined with fibroblasts to confirm similar in
ovo histology as that observed in tumors detailed in this manuscript.
Overall histology (top panels) and single cell (bottom left panel) or
collective migration (bottom right panel) are shown. Figure S5 showing
that TbRII KO epithelial cells possess a greater ability than do TbRIIfl/fl
cells to extravasate and survive post extravasation. This was quantified via
an experimental metastasis assay and subsequent murine-specific Alu
PCR (top graph). All timepoints and samples were compared with the 6-
hour timepoint of the TbRIIfl/fl cells (dashed line). Representative images
of epithelial cells (green) in relation to the lectin-labeled vasculature (red)
were taken at all timepoints to confirm extravasation quantification and
are shown beneath the graph. The 6-hour timepoint represented cells
that arrested in the vasculature. Presence of carcinoma cells in the
capillary bed, which is porous, was seen. At the 18-hour and 24-hour
timepoints, proliferative capability of disseminated tumor cells was seen.
This was evident in cells extravasating from the capillary bed and
invading into areas of the CAM in close proximity to the vasculature.
Figure S6 showing representative H & E sections of in ovo tumors.
Circled and highlighted areas of the tumor indicate which carcinoma
cells were chosen for isolation by laser capture microdissection. Figure S7
showing sections of in ovo tumors prior to (left panels) and after (middle
panels) LCM. The material obtained on the LCM cap is also shown (right
panels). Figure S8 showing that no significant differences in DDR1, Snai3,
or eIF4GI expression between TbRIIfl/fl and TbRII KO LCM tumor epithelia
were seen via quantitative PCR analysis. Only expression fold-changes of
TbRII KO LCM epithelia, as compared with TbRIIfl/fl LCM epithelia, are
shown.
Additional file 2: A representative time-lapse movie of ex ovo
TbRIIfl/fl control tumor migration monitored through intravital
imaging. Carcinoma cells and fibroblasts were xenografted together to
form the tumor, but only the carcinoma cell channel is shown. Single
cell and strand migration were observed.
Additional file 3: A representative time-lapse movie of ex ovo TbRII
KO tumor migration monitored through intravital imaging.
Carcinoma cells and fibroblasts were xenografted together to form the
tumor, but only the carcinoma cell channel is shown. A predominant
peak of collective migration was observed along with a few singly
migrating cells.
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